Melinda L. Telli
- Oncology top 0.5%
- Molecular Biology top 5%
- Cancer Research top 1%
- Pulmonary and Respiratory Medicine top 2%
- Cardiology and Cardiovascular Medicine top 2%
- Co-authors
- Ronald WittelesRobert W. CarlsonJames M. FordAlice E. GuardinoSharon A. HuntGeorge A. FisherS. SrinivasJoseph C. Wu
- Topics
- PARP inhibition in cancer therapy (35 papers)HER2/EGFR in Cancer Research (28 papers)Advanced Breast Cancer Therapies (28 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Melinda L. Telli
122 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 3.4k
- Molecular Biology 1.8k
- Cancer Research 1.7k
- Pulmonary and Respiratory Medicine 1.2k
- Cardiology and Cardiovascular Medicine 820
Countries citing papers authored by Melinda L. Telli
This map shows the geographic impact of Melinda L. Telli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melinda L. Telli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melinda L. Telli more than expected).
Fields of papers citing papers by Melinda L. Telli
This network shows the impact of papers produced by Melinda L. Telli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melinda L. Telli. The network helps show where Melinda L. Telli may publish in the future.
Co-authorship network of co-authors of Melinda L. Telli
This figure shows the co-authorship network connecting the top 25 collaborators of Melinda L. Telli. A scholar is included among the top collaborators of Melinda L. Telli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melinda L. Telli. Melinda L. Telli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 18 | |
| 4 | 7 | |
| 5 | 3 | |
| 6 | 67 | |
| 7 | 21 | |
| 8 | 76 | |
| 9 | 148 | |
| 10 | 23 | |
| 11 | 67 | |
| 12 | 88 | |
| 13 | 55 | |
| 14 | 20 | |
| 15 | 141 | |
| 16 | 55 | |
| 17 | Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicitybreakdown → | 533 |
| 18 | 137 | |
| 19 | 20 | |
| 20 | 30 |
About Melinda L. Telli
Melinda L. Telli is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 128 papers that have together received 5.4k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (35 papers), HER2/EGFR in Cancer Research (28 papers) and Advanced Breast Cancer Therapies (28 papers). The work is most often cited by research in Oncology (3.4k citations), Cancer Research (1.7k citations) and Pulmonary and Respiratory Medicine (1.2k citations). Melinda L. Telli has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ronald Witteles, Robert W. Carlson, James M. Ford, Alice E. Guardino, Sharon A. Hunt, George A. Fisher, S. Srinivas, Joseph C. Wu, Shaveta Vinayak and Allison W. Kurian. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.